Precigen (PGEN) Ends 11.6% Higher — This FDA Approval Could Hold the Reason

Precigen Inc. (NASDAQ:PGEN) is one of the 10 Stocks Paying Off Big Time.

Precigen rallied for a second day on Monday, surging 11.62 percent to end at $5.38 apiece, as investors loaded portfolios ahead of the end of the second quarter, with optimism for the period boosted by the orphan drug exclusivity of its therapy for recurrent respiratory papillomatosis (RRP).

Late last month, Precigen Inc. (NASDAQ:PGEN) secured a six-year approval from the Food and Drug Administration (FDA) to exclusively treat RRP in the US through its therapy, Papzimeos.

Alnylam (ALNY) Expands Its RNAi Therapeutics Reach Into Four More Nordic Countries

Photo by Polina Tankilevitch on Pexels

Orphan drug exclusivity is granted to certain drugs and biologics approved for rare diseases or conditions that affect fewer than 200,000 people in the United States, and will benefit Precigen Inc. (NASDAQ:PGEN) until August 14, 2032.

“This regulatory exclusivity, together with Precigen’s patent portfolio covering Papzimeos and its therapeutic use, enhances the product’s value by strengthening market protection and long-term revenue potential, which in turn supports continued innovation for rare diseases,” Precigen Inc. (NASDAQ:PGEN) President and CEO Helen Sabzevari earlier said.

While we acknowledge the risk and potential of PGEN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PGEN and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1